Anticancer Drugs

The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myel...

Full description

Saved in:
Bibliographic Details
:
Year of Publication:2019
Language:English
Physical Description:1 electronic resource (214 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993548401904498
ctrlnum (CKB)4100000010106178
(oapen)https://directory.doabooks.org/handle/20.500.12854/40955
(EXLCZ)994100000010106178
collection bib_alma
record_format marc
spelling O’Boyle, Niamh M auth
Anticancer Drugs
MDPI - Multidisciplinary Digital Publishing Institute 2019
1 electronic resource (214 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
English
graphene oxide
indole
androgens
cyclooxygenase-2
cyclooxygenase-1
heteropolysaccharide
drug conjugation
drug delivery
ellipticine
chemical linker
oesophageal cancer
antiproliferative activity
topoisomerase II
?-lactam
DSD
antibody
topoisomerase inhibitors
magnetic targeting
cisplatin resistance
steroidogenesis
[18F]FDG PET/CT
heterocyclic chemistry
dehydroepiandrosterone
antimitotic
3-vinylazetidin-2-ones
glioblastoma
and cancer therapy
intestinal mucositis
Combretastatin A-4
metabolism
anti-cancer drugs
maghemite
COX-1 inhibitor
anticancer
CYP17A1
conjugate and hybrid drugs
inflammation
snticancer drugs
P450c17
tumorigenesis
cisplatin
biomarker profiling
cancer drug design
tubulin
cytochrome P450
5-fluorouracil
prostate cancer
abiraterone
NCI screen
radiation
cancer immunotherapy
microtubule targeted drugs
cancer
treatment resistance
3-03921-586-8
Meegan, Mary J auth
language English
format eBook
author O’Boyle, Niamh M
spellingShingle O’Boyle, Niamh M
Anticancer Drugs
author_facet O’Boyle, Niamh M
Meegan, Mary J
author_variant n m o nm nmo
author2 Meegan, Mary J
author2_variant m j m mj mjm
author_sort O’Boyle, Niamh M
title Anticancer Drugs
title_full Anticancer Drugs
title_fullStr Anticancer Drugs
title_full_unstemmed Anticancer Drugs
title_auth Anticancer Drugs
title_new Anticancer Drugs
title_sort anticancer drugs
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2019
physical 1 electronic resource (214 p.)
isbn 3-03921-587-6
3-03921-586-8
illustrated Not Illustrated
work_keys_str_mv AT oboyleniamhm anticancerdrugs
AT meeganmaryj anticancerdrugs
status_str n
ids_txt_mv (CKB)4100000010106178
(oapen)https://directory.doabooks.org/handle/20.500.12854/40955
(EXLCZ)994100000010106178
carrierType_str_mv cr
is_hierarchy_title Anticancer Drugs
author2_original_writing_str_mv noLinkedField
_version_ 1787551667441369091
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03879nam-a2200925z--4500</leader><controlfield tag="001">993548401904498</controlfield><controlfield tag="005">20231214133528.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2019 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03921-587-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000010106178</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/40955</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000010106178</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">O’Boyle, Niamh M</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticancer Drugs</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (214 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">graphene oxide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">indole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgens</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclooxygenase-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclooxygenase-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heteropolysaccharide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug conjugation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ellipticine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemical linker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oesophageal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antiproliferative activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">topoisomerase II</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">?-lactam</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DSD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">topoisomerase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magnetic targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cisplatin resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">steroidogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">[18F]FDG PET/CT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heterocyclic chemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dehydroepiandrosterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimitotic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">3-vinylazetidin-2-ones</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">and cancer therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intestinal mucositis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Combretastatin A-4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-cancer drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">maghemite</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COX-1 inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP17A1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">conjugate and hybrid drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">snticancer drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">P450c17</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumorigenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cisplatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker profiling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer drug design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tubulin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytochrome P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5-fluorouracil</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abiraterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NCI screen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microtubule targeted drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment resistance</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03921-586-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meegan, Mary J</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:56:46 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-02-01 22:26:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338783130004498&amp;Force_direct=true</subfield><subfield code="Z">5338783130004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338783130004498</subfield></datafield></record></collection>